RABBIT investigates the safety and efficacy of new rheumatism drugs under everyday conditions. In contrast to controlled clinical trials, no influence is exerted on the decision as to which patient receives which medication. Clinical studies usually last only 6 to 12 months, so that they say little about the long-term tolerability and efficacy of the drugs. However, as these drugs are used for many years, it is of great importance for the patients what the long-term consequences are. Therefore RABBIT has the goal to observe every participating patient for at least 5, preferably 10 years. A second strength of RABBIT is that it also monitors the course of disease and treatment of patients who would not be included in clinical trials due to their age, concomitant diseases, a previous tumor disease or an existing pregnancy. The Registry may provide valuable and otherwise inaccessible information to these patients.
For more detailed information, see About RABBIT
The scientific results from RABBIT are highly regarded nationally and internationally. They are published in medical journals (original publications) and presented at congresses (congress contributions). Important annual congresses are the European Congress of Rheumatology (EULAR), the Congress of the German Society for Rheumatology (DGRh) and the American College of Rheumatology (ACR).